News
🌏 Asia-PacificLatest pharmaceutical news, drug approvals, and NMPA regulatory updates
Latest News
Prolacta's Human Milk-Based Fortifiers Receive World's First Prescription Drug Status in Japan Following JASMINE Trial Success
Prolacta achieves global regulatory milestone as Japan grants prescription drug status to human milk-based fortifiers for premature infants based on JASMINE trial data.
Axoft Raises $55M Series A to Advance Brain-Computer Interface Clinical Trials Globally
Axoft secures $55M Series A funding led by C.P. Group Innovation to advance bio-inspired brain-computer interface technology into global clinical trials.
Vivacta Bio Raises $50M+ Series A Funding for GT801 CAR-T Gene Therapy Development
Vivacta Biotechnology closes $50M+ Series A funding to advance GT801, an innovative in vivo CAR-T therapy for blood cancers and autoimmune diseases.
Taimei Technology Debuts AI-Powered Clinical Trial Platform at BioKorea 2026
Taimei Technology showcases AI-driven drug development platform at BioKorea 2026, planning Korea market entry with advanced clinical research solutions.
Energenesis Biomedical ENERGI-F703DFU Diabetic Foot Ulcer Treatment Data to Be Presented at EWMA 2026
Energenesis Biomedical will present clinical data for ENERGI-F703DFU gel, a novel topical treatment for diabetic foot ulcers, at EWMA 2026 in Bremen.
Ascletis Pharma to Present Diabetes Drug Data at American Diabetes Association 2026 Scientific Sessions
Ascletis Pharma will present clinical data on multiple diabetes programs at the ADA 2026 Scientific Sessions, showcasing pipeline developments in diabetes treatment.
TLX597-Tx PSMA Radioligand Therapy Shows Promise in OPTIMAL-PSMA Trial for Early-Stage Prostate Cancer
TLX597-Tx radioligand therapy demonstrates low organ toxicity in OPTIMAL-PSMA trial, potentially enabling dose intensification for prostate cancer treatment.
ImmunityBio Faces Securities Fraud Lawsuit Over Anktiva Off-Label Promotion After FDA Warning Letter
ImmunityBio hit with class action lawsuit after FDA determined company made false claims about Anktiva bladder cancer drug's capabilities beyond approved use.
ChinaBio Partnering Forum 2026: Key Takeaways and Highlights
The ChinaBio® Partnering Forum 2026 concluded April 29 in Shanghai, with panelists highlighting Ledger Run's ClinRun platform for automating clinical trial payments. While comprehensive post-event reporting remains limited, the hybrid event positioned Chinese biotechs at a critical dealmaking inflection point.
ChinaBio Partnering Forum: Biotech Deals & APAC Innovation
The ChinaBio® Partnering Forum catalyzes biotech deal-making and innovation across Asia-Pacific, with emerging focus on AI-driven drug discovery, cell and gene therapies, and regulatory harmonization reshaping the competitive landscape.
Insilico Medicine's Rentosertib Inhalation Solution Receives IND Clearance for First AI-Driven Direct-to-Lung Clinical Trial
Insilico Medicine's AI-discovered Rentosertib inhalation solution gets IND clearance for direct-to-lung delivery, marking a milestone in AI drug development.
Thailand Emerges as ASEAN Medical Device Gateway as Market Set to Reach $18.6B by 2029
Thailand positions itself as Southeast Asia's medical device hub with WHX Bangkok 2026, targeting $18.6B regional MedTech market growing at 7.31% annually.
Yangtze River Pharmaceutical Group Quadruples International Revenue in 2025 Global Expansion
Yangtze River Pharmaceutical Group reports 4x international revenue growth, doubling global partnerships while exporting 100+ products to 40+ countries.
Soleno Therapeutics Faces Securities Fraud Lawsuit Over Alleged Sham Phase 3 Clinical Trials
Soleno Therapeutics hit with securities fraud allegations claiming company conducted fraudulent Phase 3 trials that led to FDA drug approval.
Newleos Begins Phase 1b Trial of NTX-2001 for Alcohol Use Disorder Treatment
Newleos doses first patient in Phase 1b study of NTX-2001, a TAAR1 partial agonist targeting alcohol use disorder, marking key development milestone.
Citius Oncology Ships First LYMPHIR International Order to Europe, Expanding Global Cancer Treatment Access
Citius Oncology ships first international LYMPHIR order to Europe through regional distribution partners, marking major milestone in global expansion.
EirGenix Expands Japan Biosimilar Strategy at CPHI Japan 2026 Amid Regulatory Support
EirGenix leverages Japan's supportive biosimilar regulatory framework and supply chain transformation to strengthen its strategic presence in the Japanese market.
ChinaBio Partnering Forum: Biotech Deals & Investment Insights
The ChinaBio® Partnering Forum convenes Asia-Pacific biotech stakeholders to explore investment opportunities, cross-border partnerships, and emerging therapeutic innovations. The forum facilitates deal-making and strategic collaboration across the dynamic APAC biotech ecosystem.
TrialClinIQ Secures $150K Investment from Caduceus Capital to Transform Clinical Trial Recruitment with AI Technology
Houston-based TrialClinIQ raises $150K pre-seed funding and joins LAUNCH accelerator while opening $1.5M round to improve clinical trial access through AI.
Argo Biopharma Doses First Patient in Phase I Trial of siRNA Therapy BW-50218 for TTR-Related Disease
Argo Biopharma begins Phase I clinical trial of BW-50218, an siRNA therapeutic targeting transthyretin protein for rare disease treatment in Australia.